Keyword search (3,172 papers available)


Gait variability across neurodegenerative and cognitive disorders: Results from the Canadian Consortium of Neurodegeneration in Aging (CCNA) and the Gait and Brain Study.

Author(s): Pieruccini-Faria F, Black SE, Masellis M, Smith EE, Almeida QJ, Li KZH, Bherer L, Camicioli R, Montero-Odasso M...

INTRODUCTION: Gait impairment is common in neurodegenerative disorders. Specifically, gait variability-the stride-to-stride fluctuations in distance and time-has been associated with neurodegenerat...

Article GUID: 33590967

CCCDTD5 recommendations on early non cognitive markers of dementia: A Canadian consensus.

Author(s): Montero-Odasso M, Pieruccini-Faria F, Ismail Z, Li K, Lim A, Phillips N, Kamkar N, Sarquis-Adamson Y, Speechley M, Theou O, Verghese J, Wall...

Introduction: Cognitive impairment is the hallmark of Alzheimer's disease (AD) and related dementias. However, motor decline has been recently described as a prodromal state that can help to de...

Article GUID: 33094146

Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia.

Author(s): Ismail Z, Black SE, Camicioli R, Chertkow H, Herrmann N, Laforce R, Montero-Odasso M, Rockwood K, Rosa-Neto P, Seitz D, Sivananthan S, Smith...

Alzheimers Dement. 2020 Jul 29;: Authors: Ismail Z, Black SE, Camicioli R, Chertkow H, Herrmann N, Laforce R, Montero-Odasso M, Rockwood K, Rosa-Neto P, Seitz D, Sivananthan S, Smith EE, Soucy JP,...

Article GUID: 32725777

Guidelines for Gait Assessments in the Canadian Consortium on Neurodegeneration in Aging (CCNA).

Author(s): Cullen S, Montero-Odasso M, Bherer L, Almeida Q, Fraser S, Muir-Hunter S, Li K, Liu-Ambrose T, McGibbon CA, McIlroy W, Middleton LE, Sarquis...

Can Geriatr J. 2018 Jun;21(2):157-165 Authors: Cullen S, Montero-Odasso M, Bherer L, Almeida Q, Fraser S, Muir-Hunter S, Li K, Liu-Ambrose T, McGibbon CA, McIlroy W, Middleton LE, Sarquis-Adamson ...

Article GUID: 29977431

SYNERGIC TRIAL (SYNchronizing Exercises, Remedies in Gait and Cognition) a multi-Centre randomized controlled double blind trial to improve gait and cognition in mild cognitive impairment.

Author(s): Montero-Odasso M, Almeida QJ, Burhan AM, Camicioli R, Doyon J, Fraser S, Li K, Liu-Ambrose T, Middleton L, Muir-Hunter S, McIlroy W, Morais ...

BMC Geriatr. 2018 04 16;18(1):93 Authors: Montero-Odasso M, Almeida QJ, Burhan AM, Camicioli R, Doyon J, Fraser S, Li K, Liu-Ambrose T, Middleton L, Muir-Hunter S, McIlroy W, Morais JA, Pieruccini...

Article GUID: 29661156

Consensus on Shared Measures of Mobility and Cognition: From the Canadian Consortium on Neurodegeneration in Aging (CCNA).

Author(s): Montero-Odasso M, Almeida QJ, Bherer L, Burhan AM, Camicioli R, Doyon J, Fraser S, Muir-Hunter S, Li KZH, Liu-Ambrose T, McIlroy W, Middleto...

J Gerontol A Biol Sci Med Sci. 2019 May 16;74(6):897-909 Authors: Montero-Odasso M, Almeida QJ, Bherer L, Burhan AM, Camicioli R, Doyon J, Fraser S, Muir-Hunter S, Li KZH, Liu-Ambrose T, McIlroy W...

Article GUID: 30101279


Title:Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia.
Authors:Ismail ZBlack SECamicioli RChertkow HHerrmann NLaforce RMontero-Odasso MRockwood KRosa-Neto PSeitz DSivananthan SSmith EESoucy JPVedel IGauthier SCCCDTD5 participants
Link:https://www.ncbi.nlm.nih.gov/pubmed/32725777
Category:Alzheimers Dement
PMID:32725777
Dept Affiliation: PERFORM
1 Department of Psychiatry, Hotchkiss Brain Institute and O'Brien Institute for Public Health, University of Calgary, Calgary, Alberta, Canada.
2 Department of Medicine (Neurology) Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
3 Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Alberta, Canada.
4 University of Toronto, Baycrest Health Sciences, Toronto, Ontario, Canada.
5 Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
6 Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, CHU de Québec, and Faculté de Médecine, Université Laval, Laval, Québec, Canada.
7 Departments of Medicine, and Epidemiology and Biostatistics, University of Western Ontario, London, Ontario, Canada.
8 Gait and Brain Lab, Parkwood Institute, London, Ontario, Canada.
9 Dalhousie University, Halifax, Nova Scotia, Canada.
10 Neurosurgery and Psychiatry, McGill Centre for Studies in Aging, Montreal, Quebec, Canada.
11 Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
12 Alzheimer Society of Canada, Toronto, Ontario, Canada.
13 McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, PERFORM Centre, Concordia University, Montreal, Quebec, Canada.
14 Department of Family Medicine, McGill University, Montreal, Quebec, Canada.
15 Alzheimer Disease Research Unit, McGill Center for Studies in Aging, Montreal, Quebec, Canada.

Description:

Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia.

Alzheimers Dement. 2020 Jul 29;:

Authors: Ismail Z, Black SE, Camicioli R, Chertkow H, Herrmann N, Laforce R, Montero-Odasso M, Rockwood K, Rosa-Neto P, Seitz D, Sivananthan S, Smith EE, Soucy JP, Vedel I, Gauthier S, CCCDTD5 participants

Abstract

Since 1989, four Canadian Consensus Conferences on the Diagnosis and Treatment of Dementia (CCCDTD) have provided evidence-based dementia guidelines for Canadian clinicians and researchers. We present the results of the 5th CCCDTD, which convened in October 2019, to address topics chosen by the steering committee to reflect advances in the field, and build on previous guidelines. Topics included: (1) utility of the National Institute on Aging research framework for clinical Alzheimer's disease (AD) diagnosis; (2) updating diagnostic criteria for vascular cognitive impairment, and its management; (3) dementia case finding and detection; (4) neuroimaging and fluid biomarkers in diagnosis; (5) use of non-cognitive markers of dementia for better dementia detection; (6) risk reduction/prevention; (7) psychosocial and non-pharmacological interventions; and (8) deprescription of medications used to treat dementia. We hope the guidelines are useful for clinicians, researchers, policy makers, and the lay public, to inform a current and evidence-based approach to dementia.

PMID: 32725777 [PubMed - as supplied by publisher]